Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically proven recurrent ovarian cancer Failed or relapsed
after cytoreductive surgery followed by a platinum-based chemotherapy regimen Measurable
or evaluable disease Recurrent disease manifested by isolated increased levels of CA-125
and no other evaluable disease eligible if CA-125 is at least 100

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Life expectancy:
Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count
at least 100,000/mm3 Hepatic: Bilirubin no greater than upper limit of normal (ULN) ALT
and/or AST no greater than 2.5 times ULN Renal: Creatinine no greater than 2 times ULN
Neurological: No evidence of moderate peripheral neuropathy greater than grade 1 Other:
Not pregnant Fertile patients must use effective contraception No medical, social, or
psychological factors interfering with compliance

PRIOR CONCURRENT THERAPY: Biologic therapy: No prior IM-862 No concurrent biologic therapy
(e.g., interleukin-2 and interferons) Chemotherapy: See Disease Characteristics Recovered
from prior chemotherapy No concurrent antineoplastic cytotoxic agents Endocrine therapy:
Not specified Radiotherapy: Recovered from prior radiotherapy Surgery: See Disease
Characteristics Recovered from prior surgery Other: No other concurrent investigational
drugs